Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

Matched clinical trials

  • Study on the Safety and Effectiveness of BLU-222 Alone and with Drug Combination for Patients with Advanced Solid Tumors, Including Breast and Ovarian Cancer

    Not recruiting

    2 1 1 1
    Belgium France Italy Spain
  • Study of Volrustomig for Patients with Advanced Solid Tumors with Mature Tertiary Lymphoid Structures

    Not recruiting

    2 1 1
    Investigated Diseases:
    Investigated Drugs:
    France
  • Study of HST-1011 Alone and with Cemiplimab for Patients with Advanced Solid Tumors Not Responding to Standard Treatments

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Spain
  • Study of ART0380 for Patients with Advanced or Metastatic Solid Tumors

    Not recruiting

    2 1 1
    Investigated Diseases:
    France Spain
  • Study on BI-1910 and Pembrolizumab for Patients with Advanced Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Denmark Germany Poland Spain Sweden
  • Study on Larotrectinib for Treating Children with Advanced Solid Tumors with NTRK Fusion

    Not recruiting

    1 1 1
    Investigated Drugs:
    Czechia Denmark France Germany Ireland Italy +3
  • Study on Atezolizumab and Chemotherapy for Patients with Triple-Negative Breast Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    Germany Spain
  • Study of JDQ443 and Ribociclib in Combination for Adult Patients with Advanced Solid Tumors with KRAS G12C Mutation

    Not recruiting

    1 1 1 1
    Belgium France Germany Italy Spain
  • Study on How Larotrectinib Works in Adults with Solid Tumors with NTRK Gene Fusion

    Not recruiting

    2 1 1
    Investigated Drugs:
    Denmark France Germany Portugal Spain Sweden
  • Study for Patients with Advanced Malignancies: Continued Treatment with Parsaclisib Alone or with Itacitinib, Ruxolitinib, Ibrutinib, or Tafasitamab

    Not recruiting

    2 1 1 1
    Belgium Czechia Denmark France Italy Poland +2